[Federal Register Volume 62, Number 215 (Thursday, November 6, 1997)]
[Notices]
[Page 60095]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-29359]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meetings

    Pursuant to Section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
National Cancer Institute Special Emphasis Panel (SEP) meetings:

    Name of SEP: Phase II Clinical Trails of New Chemopreventive 
Agents.
    Date: November 18, 1997.
    Time: 9:00 a.m. to adjournment.
    Place: Double Tree Hotel-Rockville, 1750 Rockville Pike, 
Rockville, MD 20852.
    Contact Person: Wilna Woods, Ph.D., Scientific Review 
Administrator, National Cancer Institute, NIH, Executive Plaza 
North, Room 622B, 6130 Executive Boulevard, MSC 7405, Bethesda, MD 
20892-7405, Telephone: 301/496-7903.
    Purpose/Agenda: To review, discuss and evaluate responses to 
Request for Proposal.

    Name of SEP: Phase I Clinical Studies of Chemopreventive Agents.
    Date: November 29-20, 1997.
    Time: November 19-9:00 a.m. to recess; November 20-9:00 a.m. to 
adjournment.
    Place: Double Tree Hotel-Rockville, 1750 Rockville Pike, 
Rockville, MD 20852.
    Contact Person: Wilna Woods, Ph.D., Scientific Review 
Administrator, National Cancer Institute, NIH, Executive Plaza 
North, Room 622B, 6130 Executive Boulevard, MSC 7405, Bethesda, MD 
20892-7405, Telephone: 301/496-7903.
    Purpose/Agenda: To review, discuss and evaluate responses to 
Request for Proposal.

    This notice is being published less than 15 days prior to the 
meeting due to the urgent need to meet timing limitations imposed by 
the review and funding cycle.
    The meetings will be closed in accordance with the provisions 
set for in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. 
Proposals and the discussions could reveal confidential trade 
secrets or commercial property such as patentable material and 
personal information concerning individuals associated with the 
proposals, the disclosure of which would constitute a clearly 
unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, 
Cancer Cause and Prevention Research; 93.394, Cancer Detection and 
Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, 
Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, 
Cancer Research Manpower; 93.399, Cancer Control)

    Dated: October 30, 1997.
LaVerne Y. Stringfield,
Committee Management Officer, NIH.
[FR Doc. 97-29359 Filed 11-5-97; 8:45 am]
BILLING CODE 4140-01-M